Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Other Accumulated Expenses (2024 - 2025)

Coeptis Therapeutics Holdings has reported Other Accumulated Expenses over the past 2 years, most recently at $120000.0 for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $120000.0 for Q4 2025, down 48.94% from a year ago — trailing twelve months through Dec 2025 was $120000.0 (down 48.94% YoY), and the annual figure for FY2025 was $120000.0, down 48.94%.
  • Other Accumulated Expenses for Q4 2025 was $120000.0 at Coeptis Therapeutics Holdings, roughly flat from $120000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for COEPW hit a ceiling of $235000.0 in Q4 2024 and a floor of $120000.0 in Q3 2025.